dc.contributor.author | Rashid, JR | |
dc.contributor.author | Tsepko, Kofi | |
dc.contributor.author | Juma, FD | |
dc.date.accessioned | 2013-04-29T05:31:06Z | |
dc.date.available | 2013-04-29T05:31:06Z | |
dc.date.issued | 1992 | |
dc.identifier.citation | East Afr Med J. 1992 Jul;69(7):406-8 | en |
dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/1396201 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/17388 | |
dc.description.abstract | In this study, the investigation of hydralazine acetylator phenotype was undertaken for the first time in African hypertensives at Kenyatta National Hospital. A total of 25 randomly selected patients with moderate to severe hypertension (diastolic pressure 105-130 mmHg), participated in the phenotyping study. The phenotyping was done by administering oral standard hydralazine dose of 150 mg/day in three divided doses. The 24 hour urinary MTP/hydralazine ratio was used to categorize patients into slow and fast acetylators. Of the patients studied 69.9% were slow acetylators while 30.4% were fast acetylators. The mean 24 hour urinary MTP/hydralazine ratio for slow acetylators was 1.01 +/- 0.95. This was significantly different from the fast acetylators where the mean 24 hour urinary MTP/hydralazine ratio was 10.6 +/- 4.4 (P < 0.001). The acetylator phenotyping divided the patients into two distinct populations and no further arbitrary method was required to divide the patients into either group | en |
dc.language.iso | en | en |
dc.title | Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital. | en |
dc.type | Article | en |